Time between imaging and surgery is not a risk factor for upstaging of clinical stage IA Non-Small-Cell lung cancer

OBJECTIVES: The timing of preoperative imaging in patients with lung cancer is a debated topic, as there are limited data on cancer progression during the interval between clinical staging by imaging and pathological staging after resection. We quantified disease progression during this interval in patients with early-stage non-small cell lung cancer (NSCLC) to better understand if its length impacts upstaging. METHODS: We retrospectively reviewed our institutional database to identify patients who underwent surgery for clinically staged T1N0M0 (cT1N0M0) NSCLC from January 2015 through September 2022. Tumour upstaging between chest computed tomography (CT) and surgery were analyzed as a function of time (<30, 30-59, >= 60 days) for different nodule subtypes. We analyzed data across three timeframes using Pearson's chi-squared and ANOVA tests. RESULTS: During the study period, 622 patients underwent surgery for cT1N0M0 NSCLC. CT-to-surgery interval was <30 days in 228 (36.7%), 30-59 days in 242 (38.9%), and >= 60 days in 152 (24.4%) with no differences in patient or nodule characteristics observed between these groups. T-stage increased in 346 patients (55.6%) between CT-imaging and surgery. Among these patients, 126 (36.4%) had ground-glass nodules, 147 (42.5%) had part-solid nodules, and 73 (21.1%) had solid nodules. CT-to-surgery interval length was not associated with upstaging of any nodule subtype (full-cohort, p = 0.903; ground-glass, p = 0.880; part-solid, p = 0.858; solid, p = 0.959). CONCLUSIONS: This single-center experience suggests no significant association between tumour upstaging and time from imaging to lung resection in patients with clinical stage IA NSCLC. Further studies are needed to better understand the risk factors for upstaging.